Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00134173 · ClinicalTrials.gov registry record · Phase 3
A Coronary IVUS Study to Compare Torcetrapib/Atorvastatin to Atorvastatin Alone in Subjects With Coronary Heart Disease
A Phase 3 study of Hyperlipidemia and Coronary Disease, sponsored by Pfizer.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,100
- Enrollment target
- 20
- Study locations
NCT00134173: Completed Phase 3 study of Hyperlipidemia and Coronary Disease, sponsored by Pfizer.
NCT00134173 is a Phase 3 study of Hyperlipidemia and Coronary Disease that has completed, run by Pfizer. The registered enrollment target is 1,100 participants, above the 376-participant average among 35 other Hyperlipidemia trials with a reported enrollment target (193% higher). The trial reports 20 study locations across 6 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00134173, a Phase 3 study of Hyperlipidemia and Coronary Disease, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,100 participants
- Enrollment target
- 20
- Study locations
Study Summary
The Torcetrapib project was terminated on December 2, 2006 due to safety findings. To look at ultrasound images taken in the blood vessels of the heart and to look at various lipids in the blood of people with known coronary heart disease
Conditions Studied
Interventions
- DRUG atorvastatin
- DRUG torcetrapib/atorvastatin
Study Locations (20)
California
- Pfizer Investigational Site - Fresno
- Pfizer Investigational Site - Los Altos
- Pfizer Investigational Site - Los Angeles
- Pfizer Investigational Site - Mountain View
- Pfizer Investigational Site - Sacramento
- Pfizer Investigational Site - San Diego
- Pfizer Investigational Site - San Francisco
- Pfizer Investigational Site - Santa Rosa
- Pfizer Investigational Site - Stockton
Connecticut
- Pfizer Investigational Site - Brandford
- Pfizer Investigational Site - Farmington
- Pfizer Investigational Site - Guilford
- Pfizer Investigational Site - New Haven
Alabama
- Pfizer Investigational Site - Birmingham
- Pfizer Investigational Site - Mobile
Colorado
- Pfizer Investigational Site - Boulder
- Pfizer Investigational Site - Denver
Florida
- Pfizer Investigational Site - Atlantis
- Pfizer Investigational Site - Clearwater
Arkansas
- Pfizer Investigational Site - Little Rock
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,100 participants |
| Start Date | 2003-10 |
| Est. Completion | 2006-09 |
| Phase | Phase 3 |
What the finished NCT00134173 record still lists
NCT00134173 is an interventional study that assigns participants to a tested intervention. Its 1,100 participants enrollment target places it among the larger protocols in the corpus, above the 376-participant average among 35 other Hyperlipidemia trials with a reported enrollment target (193% higher).
The record links to 3 conditions, with Hyperlipidemia appearing as the primary indexed condition, and to 2 interventions - of which atorvastatin is the first listed.
NCT00134173 names 20 study sites across 6 states, led by California, Connecticut, Alabama.
Frequently Asked Questions
What is clinical trial NCT00134173 about?
NCT00134173 is a clinical study titled "A Coronary IVUS Study to Compare Torcetrapib/Atorvastatin to Atorvastatin Alone in Subjects With Coronary Heart Disease". The Torcetrapib project was terminated on December 2, 2006 due to safety findings. To look at ultrasound images taken in the blood vessels of the heart and to look at various lipids in the blood of people with known coronary heart disease
What is the current status of trial NCT00134173?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,100 participants. The study started on 2003-10. Estimated completion is 2006-09.
What conditions does trial NCT00134173 study?
This clinical trial studies the following conditions: Hyperlipidemia, Coronary Disease, Coronary Arteriosclerosis.
What interventions are being tested in trial NCT00134173?
The interventions under investigation include: atorvastatin (DRUG), torcetrapib/atorvastatin (DRUG).
Who is sponsoring clinical trial NCT00134173?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00134173 being conducted?
This trial has 20 study locations across Alabama, Arkansas, California, Colorado, Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hyperlipidemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00134173's enrollment target sits among peer trials
1,100 3rd of 35 higher than 33 of 35 other Hyperlipidemia trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Hyperlipidemia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Clinical Study of Enlicitide in Participants With High Cholesterol (MK-0616-037)
RECRUITING · Phase 3
-
Compassionate Use of Metreleptin in Previously Treated People With Generalized Lipodystrophy
ACTIVE NOT RECRUITING · Phase 3
-
Low Carbohydrate Diet Compared to Calorie and Fat Restricted Diet in Patients With Obesity and Type II Diabetes
COMPLETED · Phase 3
-
Changes in Lipids and Safety of Raltegravir in HIV+ Patients With Hyperlipidemia While on Current Standard Therapy
COMPLETED · Phase 3
-
Effects of Colesevelam HCl, Rosiglitazone, Sitagliptin on Control of Blood Glucose and Lipids in Type 2 Diabetes Patients Whose Blood Glucose Isn't Completely Controlled With Metformin
COMPLETED · Phase 3
-
Reduction of LDL-C With PCSK9 Inhibition in Heterozygous Familial Hypercholesterolemia Disorder Study-2
COMPLETED · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00710112 · 1,100 participants
Genetic Variants and Susceptibility to Diseases of Prematurity in Very Low Birth-Weight Infants
- NCT02688517 · 1,100 participants
Targeted Genomic Analysis of Blood and Tissue Samples From Patients With Cancer
- NCT04743765 · 1,100 participants · NA
HIP Fracture Accelerated Surgical TreaTment And Care tracK 2 Trial
- NCT05638581 · 1,100 participants · Phase 3
Trauma Resuscitation With Low-Titer Group O Whole Blood or Products
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia